用于保护和管理血液恶性病和COVID-19中的内皮损伤的Defibrotide
Edward Richardson1, Clifton C Mo2, Eleonora Calabretta3,4,5
1Department of Medicine, Warren Alpert Medical School at Brown University, Providence, RI 02903, USA.
Biomolecules
|July 29, 2025
概括
德菲布罗提德通过抗炎和抗血栓作用提供广泛的内皮保护. 本综述探讨了其在血液恶性瘤,CAR T细胞毒性和COVID-19中的应用,强调了其在各种内皮功能障碍条件中的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 德菲布罗提德已被批准用于肝脏静脉封闭性疾病 (VOD) /阴侧阻塞综合征 (SOS).
- 它具有类型的抗炎,抗血栓和纤维溶解性质.
- 这些机制赋予了内皮的保护作用,表明了更广泛的治疗潜力.
研究的目的:
- 概述了defibrotide的内皮保护机制.
- 审查目前关于defibrotide在血液恶性瘤和相关毒性的应用的证据.
- 为了探索与SARS-CoV-2感染相关的内皮质变异症中defibrotide的新兴证据.
主要方法:
- 关于defibrotide的机制和临床应用的文献综述.
- 血液恶性瘤,CAR T细胞疗法和COVID-19的综合证据摘要.
- 基于其多式联运行动,探索潜在的未来应用.
主要成果:
- 德菲布罗提德在预防/治疗肝脏VOD/SOS,移植对宿主疾病和移植相关的血栓性微血管病变方面表现出有效性.
- 它显示有潜力减轻CAR T细胞疗法和双特异抗体 (包括CRS和ICANS) 的毒性.
- 新出现的证据表明,defibrotide在与SARS-CoV-2感染相关的内皮质病中具有实用性.
结论:
- 德菲布罗提德的内皮保护性质支持其在VOD/SOS之外的使用.
- 它的应用扩展到管理先进疗法和病毒感染中的毒性.
- 德菲布罗提德代表了一种有前途的治疗药物,用于涉及内皮损伤的各种疾病.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:27Pulmonary Embolism III: Nursing Management
42
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
42
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
225
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
225
01:14Myocarditis III: Medical Management
16
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
16
01:22Myocarditis IV: Nursing Management
28
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
28
01:25Dysrhythmias VI: Management of Dysrhythmias
107
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
107